The short answer — and why it depends on more than symptom severity

Whether ChondroFiller™ is right for you is not something pain levels alone can answer — and that is the first thing clinicians emphasise at assessment. Two patients with near-identical discomfort may be triaged very differently once imaging, joint mechanics, and treatment history are reviewed.

ChondroFiller™ — also marketed as Liquid Cartilage™ — is a CE-marked Class III acellular collagen scaffold delivered as an ultrasound-guided outpatient injection. No surgery, no general anaesthetic, no operating theatre. Candidacy for it is determined through a structured consultant-led assessment, not a self-reported symptom checklist.

That assessment maps across two formal pathways. The first covers discrete, bounded cartilage lesions — the focal defect route. The second covers diffuse osteoarthritis at Kellgren-Lawrence Grade III or IV, including presentations sometimes described as 'bone on bone'. Patients previously told their damage was too extensive or too widespread for restorative options are often still eligible under one of these tracks.

Before a recommendation is made, clinicians evaluate four dimensions: joint mechanics, the biological environment, the tissue condition itself, and how wear has progressed over time. The sections below work through each in turn.

Two candidacy pathways: focal defect vs widespread osteoarthritis

Each of the two candidacy tracks carries its own clinical grading criteria and its own logic — and understanding them helps explain why the injectable route suits a broader range of patients than surgical repair alone.

The focal defect pathway

On this route, a patient has a discrete, bounded area of cartilage damage confirmed on MRI. Clinically, that damage sits at Outerbridge Grade III or IV — meaning it penetrates more than half the cartilage thickness (Grade III) or reaches the underlying subchondral bone (Grade IV). The CE-mark indication for ChondroFiller™ covers focal defects up to 6 cm² on this pathway. Common reasons patients arrive here include post-traumatic chondral lesions following significant joint injury, osteochondritis dissecans (OCD — a condition where a fragment of cartilage and its underlying bone can become partially detached), and cartilage damage secondary to meniscal tears or ligament reconstruction.

The diffuse osteoarthritis pathway

For patients with more widespread joint disease — Kellgren-Lawrence Grade III or IV, which includes presentations where joint-space narrowing is severe or 'bone on bone' contact is visible on imaging — the defect-area calculation becomes less relevant than the stage and distribution of disease across the joint. The injectable scaffold coats the articular surface as a whole rather than targeting a bounded hole, which means the size thresholds that define eligibility for surgical techniques do not apply in the same way on this track.

For context, surgical options such as microfracture are generally considered for lesions below approximately 2–4 cm², while procedures such as MACI are typically preferred from around 3 cm² upwards, each carrying dimensional requirements tied to the surgical implantation approach. The injectable scaffold sits outside that framework — a different category with different candidacy logic, not a straight comparison point.

What clinicians assess at your evaluation

At a consultant-led assessment, the clinician works through four connected questions: is the joint mechanically sound, is the biological environment free of conditions that would prevent healing, does the cartilage damage fall within a grade and pattern ChondroFiller™ can address, and how quickly has wear been progressing? The answers together — not any single factor — determine the recommendation.

MRI: required before the appointment

Patients are expected to bring a current scan so the consultation can move directly to clinical review rather than imaging planning. The MRI does three things: it confirms whether damage is focal or diffuse (mapping which candidacy track applies), grades lesion depth and geometry, and identifies features that would redirect care entirely — for instance, evidence of inflammatory arthropathy, bone oedema patterns suggesting inadequately managed subchondral disease, or joint-space loss so advanced that structural compromise has moved beyond what an injectable scaffold alone can support.

Joint mechanics

Leg malalignment beyond approximately 5°, unresolved ligament instability, or a significant meniscal deficit driving the wear must be addressed — either before injection or concurrently. Clinicians treat this as a hard requirement rather than a preference: the healing process the scaffold depends on cannot establish itself in a mechanically unsound joint.

Biological environment and tissue condition

Active joint infection, inflammatory arthritis (including rheumatoid arthritis and gout), and active malignancy are absolute exclusions — each compromises the biological environment the scaffold relies on. These are screened for at assessment, independently of imaging findings.

Wear progression and treatment history

How far disease has advanced informs whether injection alone, combination therapy, or a different pathway is most appropriate at this stage. One further prerequisite cuts across all four dimensions: conservative management — physiotherapy, anti-inflammatory medication, and prior injection therapy — should have been attempted and found inadequate before ChondroFiller™ is recommended. Candidacy is not typically confirmed at a first presentation.

Who tends to be well suited — and the age question

Age is, perhaps, the most persistent misconception patients bring to their first inquiry. Published series describe adults between roughly 40 and 65 who are active and at a healthy weight as the demographic in whom outcomes are most frequently documented — but that framing reflects who has been studied most, not a ceiling that excludes anyone older.

Clinicians are explicit on this point: there is no upper age limit. Active patients in their 60s, 70s, and beyond are a consistently highlighted candidate group, particularly those seeking to preserve the joint ahead of a replacement conversation rather than simply managing symptoms. The framing matters: this is joint-preservation medicine, not a last resort once everything else has failed. Patients who arrive at assessment hoping to delay or avoid replacement are often exactly the population the treatment was designed for.

Post-traumatic presentations make up a distinct subgroup worth naming separately. Someone who sustained a significant knee injury years earlier — a meniscal tear requiring partial meniscectomy, an anterior cruciate ligament reconstruction, or a sports-related chondral impact — may develop progressive focal damage well into their 40s or 50s, with joint mechanics that are otherwise sound. That profile sits comfortably on the focal defect pathway described in section two.

Weight and activity level are considered at assessment, but neither operates as a binary pass-or-fail criterion. They inform how well the biological environment is likely to support repair tissue formation — a clinical judgement made in context alongside imaging and mechanical findings, not a standalone threshold. A patient who is somewhat less active or carrying additional weight is not automatically excluded; the question is whether the overall picture supports a healing response.

Conditions that rule out the treatment

Several absolute contraindications extend beyond the biological-environment exclusions covered in the assessment section. Three in particular arise from the scaffold's material properties or from systemic conditions — and because they are less intuitive, patients benefit from knowing them before an appointment.

The most non-obvious is allergy to collagen or murine (mouse-derived) protein. ChondroFiller™ is a purified Type I collagen matrix of murine origin; a known sensitivity to either component rules out treatment entirely. Patients with a documented history of collagen allergy or adverse reactions to mouse-derived biological products should raise this at the earliest point of contact.

Active malignancy or a haematopoietic (blood-forming) disorder is also an absolute contraindication, as is pregnancy or breastfeeding.

These conditions are screened for systematically during the formal consultant assessment alongside the joint-mechanics and imaging review — no patient is expected to self-diagnose from this list. If any of the above apply, a clinician will discuss which alternative pathways remain appropriate, rather than simply declining treatment without further guidance.

Evidence, cost, and what happens at an assessment

The published evidence consists primarily of case series and observational cohorts, not long-term randomised controlled trials comparing the injectable route with surgical alternatives. Available series report symptom relief in a meaningful proportion of patients — figures around 70–85% appear across the published literature — but most follow-up windows run to 12–24 months. That is a short horizon when the relevant comparison is a knee replacement that might be deferred for a decade, and it is the honest frame for those numbers: promising early-to-medium-term data, not yet the consolidated long-term comparative evidence that would settle the hierarchy question definitively.

On funding, the position is straightforward. ChondroFiller™ is not NHS-funded and is not covered by major UK private medical insurers including Bupa and AXA; treatment is accessed on a private, self-funded basis. Costs are not quoted here because they vary: the volume of scaffold required differs by joint surface area and defect pattern, and the product is imported from Germany under individual prescription for each patient. Accurate pricing can only be confirmed at a formal consultation, once imaging and clinical findings have been reviewed.

Candidacy itself is determined through a structured clinical assessment, not a symptom questionnaire. For patients whose imaging and joint-mechanics findings align with the criteria described in the preceding sections, the treatment pathway is an ultrasound-guided outpatient injection — no general anaesthetic, no theatre admission. That distinction — a regenerative scaffold delivered as an in-clinic procedure — is what separates this option from surgery in the joint-preservation conversation, and mapping whether it applies to an individual case is precisely what a suitability assessment at amsk.co.uk is designed to do.